Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proton pump inhibitors and recurrent bleeding in peptic ulcer disease.

Journal of gastroenterology and hepatology - 1 Dec 2008

Tajima Akihiro, Koizumi Kazuhito, Suzuki Kazuyoshi, Higashi Naoko, Takahashi Morio, Shimada Tadahito, Terano Akira, Hiraishi Hideyuki, Kuwayama Hajime

Abstract excerpt

Peptic ulcer disease (PUD) is one of the main lesions responsible for upper gastrointestinal (GI) bleeding, as well as esophageal varices and Mallory-Weiss tear. Helicobacter pylori and non-steroidal anti-inflammatory drugs (NSAIDs)/aspirin are the major responsible causes. In cases of upper GI b...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Combined Modality Therapy
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Duodenal Ulcer

Share to Proton Pump Inhibitors

Share to Racial Groups

Share to Stomach Ulcer

Source

Identifiers

PMID: 19120905
DOI: 10.1111/j.1440-1746.2008.05557.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19120905-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proton pump inhibitors and recurrent bleeding in peptic ulcer disease.PMID 19120905Read ↗

Pathophysiology, Risk Factors, and Advances in the Management of Peptic Ulcers: A Comprehensive ReviewSemantic proximity Read ↗

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Semantic proximity Read ↗

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitorsSemantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer.Semantic proximity Read ↗

Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Prophylactic Proton Pump Inhibitors in Upper Gastrointestinal Bleeding: Impact and Underprescription in a French Multicentric CohortSemantic proximity Read ↗

Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial.Semantic proximity Read ↗

Pharmacologic Therapies in Gastrointestinal Diseases.Semantic proximity Read ↗

Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.Semantic proximity Read ↗

Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.